


Serial No. 09/891,602

Amendments to the Claims

Please amend the following claims:

Claim 1. (Previously Amended) A compound of Formula (I):



Formula (I)

wherein

Y is selected from the group consisting of a bond, -C(O)-, -C(O)O-, -C(O)NH- and -SO<sub>2</sub>-;

R<sub>1</sub> is selected from the group consisting of R<sub>7</sub> and R<sub>8</sub>;

Serial No. 09/891,602

*F' Onto*

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of a bond, hydrogen and C<sub>1-8</sub>alkyl; wherein C<sub>1-8</sub>alkyl is optionally substituted with one to three substituents independently selected from R<sub>9</sub>, provided that R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> or R<sub>5</sub> can only be a bond when forming a monocyclic ring wherein the following monocyclic rings may be formed from R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>;

when R<sub>2</sub> and R<sub>3</sub> comprise a bond and C<sub>1-8</sub>alkyl or optionally when both R<sub>2</sub> and R<sub>3</sub> are C<sub>1-8</sub>alkyl, R<sub>2</sub> and R<sub>3</sub> together with the atoms to which each is attached will form a four to seven membered monocyclic ring optionally containing one to two additional heteroatoms independently selected from the group consisting of N, O and S;

when R<sub>3</sub> and R<sub>4</sub> comprise a bond and C<sub>1-8</sub>alkyl or optionally when both R<sub>3</sub> and R<sub>4</sub> are C<sub>1-8</sub>alkyl, R<sub>3</sub> and R<sub>4</sub> together with the atoms to which each is attached will form a five to seven membered monocyclic ring optionally containing one to two additional heteroatoms independently selected from the group consisting of N, O and S;

when R<sub>3</sub> and R<sub>5</sub> comprise a bond and C<sub>1-8</sub>alkyl or optionally when both R<sub>3</sub> and R<sub>5</sub> are C<sub>1-8</sub>alkyl, R<sub>3</sub> and R<sub>5</sub> together with the atoms to which each is attached will form a four to seven membered monocyclic ring optionally containing one to two additional heteroatoms independently selected from the group consisting of N, O and S;

when R<sub>4</sub> and R<sub>5</sub> comprise a bond and C<sub>1-8</sub>alkyl, or optionally when both R<sub>4</sub> and R<sub>5</sub> are C<sub>1-8</sub>alkyl, R<sub>4</sub> and R<sub>5</sub> together with the atoms to which each is attached will form a four to seven membered monocyclic ring optionally containing one

Serial No. 09/891,602

to two additional heteroatoms independently selected from the group consisting of N, O and S;

*F1*  
*Cont'd*

R<sub>6</sub> is optionally present and is one to three substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkoxy, R<sub>10</sub>, R<sub>12</sub>, -N(R<sub>11</sub>)C(O)-R<sub>10</sub>, -N(R<sub>11</sub>)C(O)-R<sub>12</sub>, -N(R<sub>11</sub>)SO<sub>2</sub>-R<sub>10</sub>, -N(R<sub>11</sub>)SO<sub>2</sub>-R<sub>12</sub>, -N(R<sub>11</sub>)C(O)-N(R<sub>11</sub>,R<sub>10</sub>), -N(R<sub>11</sub>)C(O)-N(R<sub>11</sub>,R<sub>12</sub>), -N(R<sub>11</sub>)C(O)-N(R<sub>12</sub>,R<sub>17</sub>), -C(O)-N(R<sub>11</sub>,R<sub>10</sub>), -C(O)-N(R<sub>11</sub>,R<sub>12</sub>), -C(O)-N(R<sub>12</sub>,R<sub>17</sub>), -OC(O)-N(R<sub>11</sub>,R<sub>10</sub>), -OC(O)-N(R<sub>11</sub>,R<sub>12</sub>), -OC(O)-N(R<sub>12</sub>,R<sub>17</sub>), -OC(O)-R<sub>10</sub>, -OC(O)-R<sub>12</sub>, -O-R<sub>10</sub> and R<sub>10</sub>-(C<sub>1-8</sub>)alkoxy;

R<sub>7</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>14</sub> are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl optionally substituted with one to five substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>alkoxy, C<sub>1-8</sub>alkylcarbonyl, C<sub>1-8</sub>alkoxycarbonyl, carboxyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, amino, N-(C<sub>1-8</sub>alkyl)amino, N,N-(C<sub>1-8</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>; wherein cycloalkyl and heterocyclyl are optionally substituted with one to three oxo substituents; and, wherein the aryl and heteroaryl substituents and the aryl portion of the arylcarbonyl substituent are optionally substituted with one to five substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>alkoxy, carboxyl, amino, N-(C<sub>1-8</sub>alkyl)amino, N,N-(C<sub>1-8</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>;

R<sub>8</sub>, R<sub>12</sub>, R<sub>13</sub> and R<sub>17</sub> are independently selected from the group consisting of C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, and (halo)<sub>1-3</sub>(C<sub>1-8</sub>)alkyl; wherein C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl and C<sub>2-8</sub>alkynyl are optionally substituted on a terminal carbon

Serial No. 09/891,602

with one to three substituents independently selected from  
R<sub>14</sub>;

R<sub>11</sub> is selected from the group consisting of hydrogen and  
C<sub>1-8</sub>alkyl;

A is C<sub>1-4</sub>alkylene optionally substituted with one to two  
substituents independently selected from R<sub>13</sub>;

when R<sub>3</sub> is C<sub>1-8</sub>alkyl, optionally A and R<sub>3</sub> together with the  
atoms to which each is attached may form a five to seven  
membered monocyclic ring optionally containing one to two  
additional heteroatoms independently selected from the group  
consisting of N, O and S;


when R<sub>4</sub> is C<sub>1-8</sub>alkyl, optionally A and R<sub>4</sub> together with the  
atoms which each is attached may form a five to seven  
membered monocyclic ring optionally containing one  
additional heteroatom selected from the group consisting of  
N, O and S;

when R<sub>5</sub> is C<sub>1-8</sub>alkyl, optionally A and R<sub>5</sub> together with the  
atoms which each is attached may form a three to seven  
membered monocyclic ring optionally containing one to two  
heteroatoms independently selected from the group consisting  
of N, O and S; and,

B<sub>1</sub> and B<sub>2</sub> are independently selected from the group consisting  
of C<sub>1-2</sub>alkylene and C<sub>2</sub>alkenylene optionally substituted with  
one to two substituents independently selected from the  
group consisting of halogen, hydroxy, hydroxy(C<sub>1-8</sub>)alkyl,  
hydroxy(C<sub>1-8</sub>)alkoxy, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl,  
C<sub>1-8</sub>alkoxy, carboxyl, amino, N-(C<sub>1-8</sub>alkyl)amino,  
N,N-(C<sub>1-8</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>;

Serial No. 09/891,602

and pharmaceutically acceptable salts, racemic mixtures, diastereomers and enantiomers thereof.

 Claim 2. (Original) The compound of claim 1 wherein Y is selected from the group consisting of -C(O)- and -SO<sub>2</sub>-.

Claim 3. (Original) The compound of claim 1 wherein Y is selected from -SO<sub>2</sub>-.

Claim 4. (Original) The compound of claim 1 wherein R<sub>1</sub> is selected from R<sub>7</sub>.

Claim 5. (Original) The compound of claim 1 wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of hydrogen and C<sub>1-4</sub>alkyl.

Claim 6. (Original) The compound of claim 1 wherein R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of hydrogen and methyl.

Claim 7. (Original) The compound of claim 1 wherein R<sub>6</sub> is optionally present and is one to three substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkoxy, R<sub>10</sub>, R<sub>12</sub>, -N(R<sub>11</sub>)C(O)-R<sub>10</sub>, -N(R<sub>11</sub>)C(O)-R<sub>12</sub>, -N(R<sub>11</sub>)SO<sub>2</sub>-R<sub>10</sub>-, -N(R<sub>11</sub>)C(O)-N(R<sub>11</sub>, R<sub>12</sub>), -N(R<sub>11</sub>)C(O)-N(R<sub>12</sub>, R<sub>17</sub>), -OC(O)-N(R<sub>11</sub>, R<sub>12</sub>), -OC(O)-N(R<sub>12</sub>, R<sub>17</sub>), -OC(O)-R<sub>10</sub> and R<sub>10</sub>-(C<sub>1-8</sub>)alkoxy.

Claim 8. (Original) The compound of claim 1 wherein R<sub>6</sub> is optionally present and is one to three substituents independently selected from the group consisting of halogen,

Serial No. 09/891,602

C<sub>1-4</sub>alkoxy, R<sub>10</sub>, R<sub>12</sub>, -N(R<sub>11</sub>)C(O)-R<sub>10</sub>, -N(R<sub>11</sub>)C(O)-R<sub>12</sub>, -N(R<sub>11</sub>)SO<sub>2</sub>-R<sub>10</sub>-, -N(R<sub>11</sub>)C(O)-N(R<sub>11</sub>,R<sub>12</sub>), -N(R<sub>11</sub>)C(O)-N(R<sub>12</sub>,R<sub>17</sub>), -OC(O)-N(R<sub>11</sub>,R<sub>12</sub>), -OC(O)-N(R<sub>12</sub>,R<sub>17</sub>), -OC(O)-R<sub>10</sub> and R<sub>10</sub>-(C<sub>1-4</sub>)alkoxy.

Claim 9. (Original) The compound of claim 1 wherein R<sub>6</sub> is optionally present and is one to two substituents independently selected from the group consisting of R<sub>10</sub>, -N(R<sub>11</sub>)C(O)-R<sub>10</sub>, -N(R<sub>11</sub>)C(O)-N(R<sub>11</sub>,R<sub>12</sub>), -N(R<sub>11</sub>)C(O)-N(R<sub>12</sub>,R<sub>17</sub>), -OC(O)-N(R<sub>11</sub>,R<sub>12</sub>), -OC(O)-N(R<sub>12</sub>,R<sub>17</sub>) and R<sub>10</sub>-methoxy.

Claim 10. (Original) The compound of claim 1 wherein R<sub>7</sub> is selected from the group consisting of aryl and heteroaryl optionally substituted with one to five substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>alkoxy, C<sub>1-8</sub>alkylcarbonyl, C<sub>1-8</sub>alkoxycarbonyl, carboxyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, amino, N-(C<sub>1-8</sub>alkyl)amino, N,N-(C<sub>1-8</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>; and, wherein the aryl and heteroaryl substituents and the aryl portion of the arylcarbonyl substituent are optionally substituted with one to five substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>alkoxy, carboxyl, amino, N-(C<sub>1-8</sub>alkyl)amino, N,N-(C<sub>1-8</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>.

Claim 11. (Original) The compound of claim 1 wherein R<sub>10</sub> is selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl optionally substituted with one to five substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkyl, C<sub>1-8</sub>alkoxy, C<sub>1-8</sub>alkoxycarbonyl, carboxyl, arylcarbonyl, arylsulfonyl, -CF<sub>3</sub> and -OCF<sub>3</sub>; wherein cycloalkyl and heterocyclyl are optionally substituted with one to three oxo substituents; and, wherein the aryl portion

Serial No. 09/891,602

of the arylcarbonyl substituent is optionally substituted with one to five substituents independently selected from C<sub>1-8</sub>alkoxy.

FI  
Conty

Claim 12. (Original) The compound of claim 1 wherein R<sub>10</sub> is selected from the group consisting of cyclopropyl, 1,3-dihydro-2H-isoindolyl, 2-azabicyclo[2.2.2]octyl, piperidinyl, morpholinyl, phenyl, naphthalenyl, thienyl, 1H-pyrrolyl and pyridinyl; wherein cyclopropyl, piperidinyl, morpholinyl, phenyl, naphthalenyl, thienyl, 1H-pyrrolyl and pyridinyl are optionally substituted with one to four substituents independently selected from the group consisting of chlorine, fluorine, bromine, methyl, isopropyl, t-butyl, methoxy, t-butoxycarbonyl, carboxyl, phenylcarbonyl, -CF<sub>3</sub> and -OCF<sub>3</sub>; wherein 1,3-dihydro-2H-isoindolyl is optionally substituted with oxo; wherein 2-azabicyclo[2.2.2]octyl is optionally substituted with phenylsulfonyl, and, wherein the phenyl portion of the phenylcarbonyl substituent is optionally substituted with one to two substituents independently selected from methoxy.

Claim 13. (Original) The compound of claim 1 wherein R<sub>12</sub> is selected from the group consisting of C<sub>1-8</sub>alkyl and C<sub>2-8</sub>alkynyl optionally substituted on a terminal carbon with R<sub>14</sub>.

Claim 14. (Original) The compound of claim 1 wherein R<sub>12</sub> is selected from the group consisting of C<sub>1-4</sub>alkyl and C<sub>2-4</sub>alkynyl optionally substituted on a terminal carbon with R<sub>14</sub>.

Claim 15. (Original) The compound of claim 1 wherein R<sub>12</sub> is selected from the group consisting of t-butyl and ethynyl; wherein ethynyl is optionally substituted on a terminal carbon with a substituent independently selected from R<sub>14</sub>.

Serial No. 09/891,602

*F1*  
*Contd*

Claim 16. (Original) The compound of claim 1 wherein  $R_{14}$  is selected from the group consisting of aryl optionally substituted with one to five substituents independently selected from the group consisting of halogen,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{1-8}$ alkoxy,  $C_{1-8}$ alkylcarbonyl,  $C_{1-8}$ alkoxycarbonyl, carboxyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, amino,  $N$ -( $C_{1-8}$ alkyl)amino,  $N,N$ -( $C_{1-8}$ dialkyl)amino,  $-CF_3$  and  $-OCF_3$ ; and, wherein the aryl and heteroaryl substituents and the aryl portion of the arylcarbonyl substituent are optionally substituted with one to five substituents independently selected from the group consisting of halogen,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{1-8}$ alkoxy, carboxyl, amino,  $N$ -( $C_{1-8}$ alkyl)amino,  $N,N$ -( $C_{1-8}$ dialkyl)amino,  $-CF_3$  and  $-OCF_3$ .

Claim 17. (Original) The compound of claim 1 wherein  $R_{11}$  is selected from the group consisting of hydrogen and  $C_{1-4}$ alkyl.

Claim 18. (Original) The compound of claim 1 wherein  $R_{11}$  is hydrogen.

Claim 19. (Original) The compound of claim 1 wherein A is selected from the group consisting of methylene and ethylene.

Claim 20. Canceled

<sup>20</sup>  
Claim 21. (Original) The compound of claim 1 wherein  $B_1$  and  $B_2$  are independently selected from the group consisting of  $-CH_2-$ ,  $-(CH_2)_2-$  and  $-(CH)_2-$  optionally substituted with one to two substituents independently selected from the group consisting of halogen, hydroxy, hydroxy( $C_{1-4}$ )alkyl, hydroxy( $C_{1-4}$ )alkoxy,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,




Serial No. 09/891,602

C<sub>1-4</sub>alkoxy, carboxyl, amino, N-(C<sub>1-4</sub>alkyl)amino, N,N-(C<sub>1-4</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>.

*Final*  
21  
Claim 22. (Original) The compound of claim 1 wherein B<sub>1</sub> is selected from the group consisting of -CH<sub>2</sub>-, -(CH<sub>2</sub>)<sub>2</sub>- and -(CH)<sub>2</sub>- optionally substituted with one to two substituents independently selected from the group consisting of halogen, hydroxy, hydroxy(C<sub>1-4</sub>)alkyl, hydroxy(C<sub>1-4</sub>)alkoxy, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, carboxyl, amino, N-(C<sub>1-4</sub>alkyl)amino, N,N-(C<sub>1-4</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>; and, wherein, B<sub>2</sub> is selected from -(CH<sub>2</sub>)<sub>2</sub>-.

22  
Claim 23. (Original) The compound of claim 1 wherein B<sub>1</sub> is selected from the group consisting of -CH<sub>2</sub>-, -(CH<sub>2</sub>)<sub>2</sub>- and -(CH)<sub>2</sub>-.

23  
Claim 24. (Original) The compound of claim 1 wherein the compound of Formula (I) is selected from a compound of the formula:




wherein B<sub>1</sub>, R<sub>1</sub>, R<sub>3</sub>, R<sub>5</sub>, A and R<sub>6</sub> are dependently selected from the group consisting of:

Serial No. 09/891,602

B <sub>1</sub>	R <sub>1</sub>	R <sub>3</sub>	R <sub>5</sub>	A	R <sub>6</sub>
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O) - (2,6-Cl <sub>2</sub> ) Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O) - (2,4,6-Cl <sub>3</sub> ) Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O) - [2,6-(OMe) <sub>2</sub> ] Ph;
	Tol				
CH <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-NHC(O) - (2,6-F <sub>2</sub> ) Ph;
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-NHC(O) - (2,6-Cl <sub>2</sub> ) Ph;
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-[2,6-(OMe) <sub>2</sub> ] Ph;
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O) - (2-Me) Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O) - (2-Cl) Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O) - (2,6-F <sub>2</sub> ) Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O) - (2-CF <sub>3</sub> ) Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O) - (2-OCF <sub>3</sub> ) Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O) - (2-Br) Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-NHC(O) - (2,6-F <sub>2</sub> ) Ph;
CH <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-NHC(O) - (2,6-Cl <sub>2</sub> ) Ph;
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-[2,6-(OMe) <sub>2</sub> ] Ph;
	Tol				
CH <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-NHC(O) - [2,6-(OMe) <sub>2</sub> ] Ph;
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-CC-(4-t-butyl) Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-CC-Ph;
	- -				

Serial No. 09/891,602



	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O)-Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O)-[4-C(O)-[2,5-(OMe) <sub>2</sub> ]Ph]Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O)-CH <sub>2</sub> -(2,6-Cl <sub>2</sub> )Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-NHC(O)-NH-(2,6-Cl <sub>2</sub> )Ph;
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-OCH <sub>2</sub> -(2,6-Cl <sub>2</sub> )Ph;
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-OCH <sub>2</sub> -Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-NHC(O)-(2,4,6-isopropyl <sub>3</sub> )Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-(1H-pyrrol-1-yl);
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	4-Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-NHC(O)-NH-(2,6-F <sub>2</sub> )Ph;
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	3-NHC(O)-(2,6-F <sub>2</sub> )Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	3-NHC(O)-[2,6-(OMe) <sub>2</sub> ]Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	4-	H	H	CH <sub>2</sub>	3-NHC(O)-(2,6-Cl <sub>2</sub> )Ph;
	Tol				
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	CH <sub>3</sub>	CH <sub>2</sub>	4-OCH <sub>2</sub> -(2,6-Cl <sub>2</sub> )Ph;
(CH <sub>2</sub> ) <sub>2</sub>	Ph	CH <sub>3</sub>	H	CH <sub>2</sub>	4-NHC(O)-(2,6-Cl <sub>2</sub> )Ph;
(CH) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-OCH <sub>2</sub> -(2,6-Cl <sub>2</sub> )Ph;
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-OCH <sub>2</sub> -(2,6-Cl <sub>2</sub> )Ph;
(CH) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-NHC(O)-(2,6-Cl <sub>2</sub> )Ph;
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-(2,4,6-F <sub>3</sub> )Ph;

Serial No. 09/891,602

$(CH_2)_2$  Ph H H  $CH_2$  4-(2,3,5,6-F<sub>4</sub>)Ph;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-O-t-butoxy;  
 $(CH_2)_2$  Ph H H  $(CH_2)_2$  ---;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl);  
 $(CH_2)_2$  Ph H H  $CH_2$  4-NHC(O)-(2-CO<sub>2</sub>H)Ph;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-(2,5-diMe-1H-pyrrol-1-yl);  
 $(CH_2)_2$  Ph H H  $CH_2$  4-NHC(O)-4-pyridinyl;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-NHSO<sub>2</sub>-(2,6-Cl<sub>2</sub>)Ph;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-OC(O)-N(CH<sub>3</sub>)<sub>2</sub>;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-NHC(O)-(1-t-butoxycarbonyl)4-piperidinyl;  
 $(CH_2)_2$  4-FPh H H  $CH_2$  4-NHC(O)-(2,6-Cl<sub>2</sub>)Ph;  
 $(CH_2)_2$  4-FPh H H  $CH_2$  4-NHC(O)-[2,6-(OMe)<sub>2</sub>]Ph;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-OC(O)-4-morpholinyl;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-OC(O)N(iso-propyl)<sub>2</sub>;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-t-butyl;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-NHC(O)-4-piperidinyl;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-NHC(O)-(3,5-Cl<sub>2</sub>)4-pyridinyl;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-NHC(O)-NMe<sub>2</sub>;  
 $(CH_2)_2$  Ph H H  $CH_2$  3-F-4-[OCH<sub>2</sub>(2,6-Cl<sub>2</sub>)Ph];  
 $(CH_2)_2$  2-Thi H H  $CH_2$  4-OC(O)-NMe<sub>2</sub>;  
 $(CH_2)_2$  Ph H H  $CH_2$  4-NHC(O)-t-butyl;

Serial No. 09/891,602

(CH<sub>2</sub>)<sub>2</sub> Ph H H CH<sub>2</sub> 4-NHC(O)-(2-OMe)1-naphthalenyl;  
 (CH<sub>2</sub>)<sub>2</sub> 2- Thi H H CH<sub>2</sub> 4-NHC(O)-(2,6-Cl<sub>2</sub>)Ph;  
 (CH<sub>2</sub>)<sub>2</sub> Ph H H CH<sub>2</sub> 4-NHC(O)-cyclopropyl;  
 (CH<sub>2</sub>)<sub>2</sub> Ph H H CH<sub>2</sub> 4-NHC(O)-(2,2,3,3-Me<sub>4</sub>)cyclopropyl;  
 (CH<sub>2</sub>)<sub>2</sub> Ph H H CH<sub>2</sub> 4-NHC(O)-iso-propyl;  
 (CH<sub>2</sub>)<sub>2</sub> Ph H H CH<sub>2</sub> 4-NHC(O)-(2-SO<sub>2</sub>Ph)-2-azabicyclo[2.2.2]oct-3-yl;  
 (CH<sub>2</sub>)<sub>2</sub> 2- Thi H H CH<sub>2</sub> 4-NHC(O)-(3,5-Cl<sub>2</sub>)4-pyridinyl;  
 (CH<sub>2</sub>)<sub>2</sub> Ph H H CH<sub>2</sub> 4-NHC(O)-(2-Me)cyclopropyl;  
 (CH<sub>2</sub>)<sub>2</sub> Ph H H CH<sub>2</sub> 4-(2,6-diMe)Ph;  
 (CH<sub>2</sub>)<sub>2</sub> Ph H H CH<sub>2</sub> 4-(2,6-Cl<sub>2</sub>)Ph;  
 (CH<sub>2</sub>)<sub>2</sub> 2- Thi H H CH<sub>2</sub> 4-(2,6-Cl<sub>2</sub>)Ph;  
 (CH<sub>2</sub>)<sub>2</sub> 2- Thi H H CH<sub>2</sub> 4-(2,6-diMe)Ph;  
 (CH<sub>2</sub>)<sub>2</sub> 2- Thi H H CH<sub>2</sub> 4-[2,6-(OMe)<sub>2</sub>]Ph;  
 (CH<sub>2</sub>)<sub>2</sub> 2- Thi H H CH<sub>2</sub> 4-(4-fluoro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl);  
 (CH<sub>2</sub>)<sub>2</sub> 2- Thi H H CH<sub>2</sub> 4-NHC(O)-NMe<sub>2</sub>;  
 (CH<sub>2</sub>)<sub>2</sub> 2- Thi H H CH<sub>2</sub> 4-OC(O)-NMe<sub>2</sub>;  
 (CH<sub>2</sub>)<sub>2</sub> 2- Thi H H CH<sub>2</sub> 4-OC(O)-(4-morpholinyl);

Serial No. 09/891,602

*Handwritten:*  
F1  
Cm

	Thi				
(CH <sub>2</sub> ) <sub>2</sub>	2-	H	H	CH <sub>2</sub>	4-OC(O) - (4-Me-1-piperazinyl);
	Thi				
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-OC(O) - (4-Me-1-piperazinyl);
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-N(Me)C(O) - (2,6-Cl <sub>2</sub> )Ph;
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-N(Me)C(O) - (3,5-Cl <sub>2</sub> )4-pyridinyl;
(CH <sub>2</sub> ) <sub>2</sub>	2-	H	H	CH <sub>2</sub>	4-N(Me)C(O) - (3,5-Cl <sub>2</sub> )4-pyridinyl;
	Thi				
(CH <sub>2</sub> ) <sub>2</sub>	2-	H	H	CH <sub>2</sub>	4-N(Me)C(O) - (2,6-Cl <sub>2</sub> )Ph;
	Thi				
(CH <sub>2</sub> ) <sub>2</sub>	2-	H	H	CH <sub>2</sub>	4-OCH <sub>2</sub> - (2,6-Cl <sub>2</sub> )Ph;
	Thi				
(CH <sub>2</sub> ) <sub>2</sub>	2-	H	H	CH <sub>2</sub>	4-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl);
	Thi				
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-(1,3-dihydro-4,7-dimethyl-1,3-dioxo-2H-isoindol-2-yl);
(CH <sub>2</sub> ) <sub>2</sub>	2-	H	H	CH <sub>2</sub>	4-(1,3-dihydro-4,7-dimethyl-1,3-dioxo-2H-isoindol-2-yl);
	Thi				
CH <sub>2</sub>	2-	H	H	CH <sub>2</sub>	4-NHC(O) - (3,5-Cl <sub>2</sub> )4-pyridinyl;
	Thi				
CH <sub>2</sub>	2-	H	H	CH <sub>2</sub>	4-NHC(O) - (2,6-Cl <sub>2</sub> )Ph;
	Thi				
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-(1,1-dioxido-3-oxo-1,2-benzisothiazol-2(3H)-yl);
(CH <sub>2</sub> ) <sub>2</sub>	Ph	H	H	CH <sub>2</sub>	4-(4-chloro-1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl);


Serial No. 09/891,602

and,

(CH<sub>2</sub>)<sub>2</sub>    Ph    H    H    CH<sub>2</sub>    4-(7,9-dioxo-8-  
azaspiro[4.5]dec-8-yl);

and pharmaceutically acceptable salts, racemic mixtures,  
diastereomers and enantiomers thereof.

24  
Claim 25. (Previously Amended) A compound having Formula  
(II):



Formula (II)

wherein

Y is selected from the group consisting of -C(O)- and -SO<sub>2</sub>-;

R<sub>1</sub> is selected from the group consisting of R<sub>7</sub> and R<sub>8</sub>;

Serial No. 09/891,602

*File*

R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are independently selected from the group consisting of a bond, hydrogen and C<sub>1-8</sub>alkyl; wherein C<sub>1-8</sub>alkyl is optionally substituted with one to three substituents independently selected from R<sub>9</sub>; provided that R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> can only be a bond when forming a monocyclic ring wherein the following monocyclic rings may be formed from R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub>:

when R<sub>2</sub> and R<sub>3</sub> comprise a bond and C<sub>1-8</sub>alkyl or optionally when both R<sub>2</sub> and R<sub>3</sub> are C<sub>1-8</sub>alkyl, R<sub>2</sub> and R<sub>3</sub> together with the atoms to which each are attached form a four to seven membered monocyclic ring optionally containing one to two additional heteroatoms independently selected from the group consisting of N, O and S;

when R<sub>3</sub> and R<sub>4</sub> comprise a bond and C<sub>1-8</sub>alkyl or optionally when both R<sub>3</sub> and R<sub>4</sub> are C<sub>1-8</sub>alkyl, R<sub>3</sub> and R<sub>4</sub> together with the atoms to which each are attached form a five to seven membered monocyclic ring optionally containing one to two additional heteroatoms independently selected from the group consisting of N, O and S;

when R<sub>3</sub> and R<sub>5</sub> comprise a bond and C<sub>1-8</sub>alkyl or optionally when both R<sub>3</sub> and R<sub>5</sub> are C<sub>1-8</sub>alkyl, R<sub>3</sub> and R<sub>5</sub> together with the atoms to which each are attached form a four to seven membered monocyclic ring optionally containing one to two additional heteroatoms independently selected from the group consisting of N, O and S;

when R<sub>4</sub> and R<sub>5</sub> comprise a bond and C<sub>1-8</sub>alkyl or optionally when both R<sub>4</sub> and R<sub>5</sub> are C<sub>1-8</sub>alkyl, R<sub>4</sub> and R<sub>5</sub> together with the atoms to which each are attached form a four to seven membered monocyclic ring optionally containing one to two



Serial No. 09/891,602

additional heteroatoms independently selected from the group consisting of N, O and S;

*FI*  
*contd*

R<sub>6</sub> is optionally present and is one to three substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkoxy, R<sub>10</sub>, R<sub>12</sub>, -N(R<sub>11</sub>)C(O)-R<sub>10</sub>, -N(R<sub>11</sub>)C(O)-R<sub>12</sub>, -N(R<sub>11</sub>)SO<sub>2</sub>-R<sub>10</sub>, -N(R<sub>11</sub>)SO<sub>2</sub>-R<sub>12</sub>, -N(R<sub>11</sub>)C(O)-N(R<sub>11</sub>,R<sub>10</sub>), -N(R<sub>11</sub>)C(O)-N(R<sub>11</sub>,R<sub>12</sub>), -N(R<sub>11</sub>)C(O)-N(R<sub>12</sub>,R<sub>17</sub>), -C(O)-N(R<sub>11</sub>,R<sub>10</sub>), -C(O)-N(R<sub>11</sub>,R<sub>12</sub>), -C(O)-N(R<sub>12</sub>,R<sub>17</sub>), -OC(O)-N(R<sub>11</sub>,R<sub>10</sub>), -OC(O)-N(R<sub>11</sub>,R<sub>12</sub>), -OC(O)-N(R<sub>12</sub>,R<sub>17</sub>), -OC(O)-R<sub>10</sub>, -OC(O)-R<sub>12</sub>, -O-R<sub>10</sub> and R<sub>10</sub>-(C<sub>1-8</sub>)alkoxy;

R<sub>7</sub>, R<sub>9</sub>, R<sub>10</sub> and R<sub>14</sub> are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl optionally substituted with one to five substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>alkoxy, C<sub>1-8</sub>alkylcarbonyl, C<sub>1-8</sub>alkoxycarbonyl, carboxyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, amino, N-(C<sub>1-8</sub>alkyl)amino, N,N-(C<sub>1-8</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>; wherein cycloalkyl and heterocyclyl are optionally substituted with one to three oxo substituents; and, wherein the aryl and heteroaryl substituents and the aryl portion of the arylcarbonyl substituent are optionally substituted with one to five substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>alkoxy, carboxyl, amino, N-(C<sub>1-8</sub>alkyl)amino, N,N-(C<sub>1-8</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>;

R<sub>8</sub>, R<sub>12</sub>, R<sub>13</sub> and R<sub>17</sub> are independently selected from the group consisting of C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, and (halo)<sub>1-3</sub>(C<sub>1-8</sub>)alkyl; wherein C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl and C<sub>2-8</sub>alkynyl are optionally substituted on a terminal carbon

Serial No. 09/891,602

with one to three substituents independently selected from  $R_{14}$ ;

$R_{11}$  is selected from the group consisting of hydrogen and  $C_{1-8}$ alkyl;

A is  $C_{1-4}$ alkylene optionally substituted with one to two substituents independently selected from  $R_{13}$ ;

when  $R_3$  is  $C_{1-8}$ alkyl, optionally A and  $R_3$  together with the atoms to which each is attached form a five to seven membered monocyclic ring optionally containing one to two additional heteroatoms independently selected from the group consisting of N, O and S;

when  $R_4$  is  $C_{1-8}$ alkyl, optionally A and  $R_4$  together with the atoms to which each is attached form a five to seven membered monocyclic ring optionally containing one additional heteroatom selected from the group consisting of N, O and S;

when  $R_5$  is  $C_{1-8}$ alkyl, optionally A and  $R_5$  together with the atoms to which each is attached form a three to seven membered monocyclic ring optionally containing one to two heteroatoms independently selected from the group consisting of N, O and S;


B is selected from the group consisting of  $C_{1-2}$ alkylene and  $C_2$ alkenylene optionally substituted with one to two substituents independently selected from the group consisting of halogen, hydroxy, hydroxy( $C_{1-8}$ )alkyl, hydroxy( $C_{1-8}$ )alkoxy,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{1-8}$ alkoxy, carboxyl, amino,  $N$ -( $C_{1-8}$ alkyl)amino,  $N,N$ -( $C_{1-8}$ dialkyl)amino,  $-CF_3$  and  $-OCF_3$ ; and,

Serial No. 09/891,602

n is an integer from 1 to 2;

and pharmaceutically acceptable salts, racemic mixtures, diastereomers and enantiomers thereof.

*25*  
Claim ~~26~~. (Currently Amended) A process for preparing a compound of Formula (III):



Formula (III)

wherein

R<sub>1</sub> is selected from the group consisting of R<sub>7</sub> and R<sub>8</sub>;

R<sub>7</sub>, R<sub>10</sub>, and R<sub>14</sub> are independently selected from the group consisting of cycloalkyl, heterocyclyl, aryl and heteroaryl

Serial No. 09/891,602

optionally substituted with one to five substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>alkoxy, C<sub>1-8</sub>alkylcarbonyl, C<sub>1-8</sub>alkoxycarbonyl, carboxyl, aryl, heteroaryl, arylcarbonyl, heteroarylcarbonyl, arylsulfonyl, amino, N-(C<sub>1-8</sub>alkyl)amino, N,N-(C<sub>1-8</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>; wherein cycloalkyl and heterocyclyl are optionally substituted with one to three oxo substituents; and, wherein the aryl and heteroaryl substituents and the aryl portion of the arylcarbonyl substituent are optionally substituted with one to five substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, C<sub>1-8</sub>alkoxy, carboxyl, amino, N-(C<sub>1-8</sub>alkyl)amino, N,N-(C<sub>1-8</sub>dialkyl)amino, -CF<sub>3</sub> and -OCF<sub>3</sub>;

R<sub>8</sub>, R<sub>12</sub> and R<sub>17</sub> are independently selected from the group consisting of C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl, C<sub>2-8</sub>alkynyl, and (halo)<sub>1-3</sub>(C<sub>1-8</sub>)alkyl; wherein C<sub>1-8</sub>alkyl, C<sub>2-8</sub>alkenyl and C<sub>2-8</sub>alkynyl are optionally substituted on a terminal carbon with one to three substituents independently selected from R<sub>14</sub>;

R<sub>15</sub> R<sub>15</sub> is selected from the group consisting of hydroxy, amino, NO<sub>2</sub> and R<sub>6</sub>;

R<sub>6</sub> is optionally present and is one to three substituents independently selected from the group consisting of halogen, C<sub>1-8</sub>alkoxy, R<sub>10</sub>, R<sub>12</sub>, -N(R<sub>11</sub>)C(O)-R<sub>10</sub>, -N(R<sub>11</sub>)C(O)-R<sub>12</sub>, -N(R<sub>11</sub>)SO<sub>2</sub>-R<sub>10</sub>, -N(R<sub>11</sub>)SO<sub>2</sub>-R<sub>12</sub>, -N(R<sub>11</sub>)C(O)-N(R<sub>11</sub>, R<sub>10</sub>), -N(R<sub>11</sub>)C(O)-N(R<sub>11</sub>, R<sub>12</sub>), -N(R<sub>11</sub>)C(O)-N(R<sub>12</sub>, R<sub>17</sub>), -C(O)-N(R<sub>11</sub>, R<sub>10</sub>), -C(O)-N(R<sub>12</sub>, R<sub>17</sub>), -C(O)-N(R<sub>11</sub>, R<sub>12</sub>), -OC(O)-N(R<sub>11</sub>, R<sub>10</sub>), -OC(O)-N(R<sub>11</sub>, R<sub>12</sub>), -OC(O)-N(R<sub>12</sub>, R<sub>17</sub>), -OC(O)-R<sub>10</sub>, -OC(O)-R<sub>12</sub>, -O-R<sub>10</sub> and R<sub>10</sub>-(C<sub>1-8</sub>)alkoxy;


Serial No. 09/891,602

$R_{11}$  is selected from the group consisting of hydrogen and  $C_{1-8}$ alkyl; and,


$B_1$  and  $B_2$  are independently selected from the group consisting of  $C_{1-8}$ alkylene and  $C_2$ alkenylene optionally substituted with one to two substituents independently selected from the group consisting of halogen, hydroxy, hydroxy( $C_{1-8}$ )alkyl, hydroxy( $C_{1-8}$ )alkoxy,  $C_{1-8}$ alkyl,  $C_{2-8}$ alkenyl,  $C_{2-8}$ alkynyl,  $C_{1-8}$ alkoxy, carboxyl, amino,  $N$ -( $C_{1-8}$ alkyl)amino,  $N,N$ -( $C_{1-8}$ dialkyl)amino,  $-CF_3$  and  $-OCF_3$ ;

and pharmaceutically acceptable salts, racemic mixtures, diastereomers and enantiomers thereof;

comprising reacting a compound of Formula (IV)



Formula (IV)




Formula (IV)

Serial No. 09/891,602

wherein

R<sub>15</sub> is selected from the group consisting of halogen, mixed anhydride and hydroxy;

with a compound of Formula (V)




Formula (V);

in the presence of appropriate coupling agents, bases and solvents to form the compound of Formula (II).


26  
Claim 27. (Original) The process of claim 25 wherein R<sub>15</sub> is selected from the group consisting of hydroxy, iodine, bromine and NO<sub>2</sub>.

27  
Claim 28. (Original) The compound of claim 1 wherein the compound of Formula (I) is selected from a compound of the formula:

Serial No. 09/891,602




<sup>28</sup>  
Claim 29. (Original) The compound of claim 1 wherein the compound of Formula (I) is selected from a compound of the formula:




<sup>29</sup>  
Claim 30. (Original) The compound of claim 1 wherein the compound of Formula (I) is selected from a compound of the formula:

Serial No. 09/891,602



*30*  
Claim ~~31~~. (Original) The compound of claim 1 wherein the compound of Formula (I) is selected from a compound of the formula:



*31*  
Claim ~~32~~. (Original) The compound of claim 1 wherein the compounds are effective antagonists of an integrin receptor.

*32* *31*  
Claim ~~33~~. (Original) The compound of claim ~~32~~ wherein the compound is a selective antagonist of an  $\alpha 4$  integrin receptor.



Serial No. 09/891,602

<sup>33</sup>  
Claim ~~34~~. (Original) The compound of claim <sup>32</sup>~~33~~ wherein the  $\alpha 4$  integrin receptor is selected from the group consisting of the  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  integrin receptor.

<sup>34</sup>  
Claim ~~35~~. (Original) The compound of claim <sup>31</sup>~~32~~ wherein the compound is an antagonist of at least two  $\alpha 4$  integrin receptors.

<sup>35</sup>  
Claim ~~36~~. (Original) The compound of claim <sup>34</sup>~~35~~ wherein the two  $\alpha 4$  integrin receptors are selected from the group consisting of the  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  integrin receptor.

Claims 37-43 (Canceled)

<sup>36</sup>  
Claim ~~44~~. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

<sup>37</sup>  
Claim ~~45~~. (Original) A pharmaceutical composition made by mixing a compound of claim 1 and a pharmaceutically acceptable carrier.

<sup>38</sup>  
Claim ~~46~~. (Original) A method for the treatment of an integrin mediated disorder ameliorated by inhibition of an  $\alpha 4$  integrin receptor comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

Claim 47. (Canceled)

<sup>39</sup>  
Claim ~~48~~. (Original) The method of claim <sup>38</sup>~~47~~ wherein the  $\alpha 4$  integrin receptor is selected from the group consisting of the  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  integrin receptor.

Serial No. 09/891,602

*FD*  
*CHD*  
Claim <sup>40</sup>~~48~~. (Original) The method of claim <sup>38</sup>~~46~~ wherein the compound inhibiting the  $\alpha 4$  integrin receptor is selected from the group consisting of a selective antagonist of the  $\alpha 4\beta 1$  integrin receptor, a selective antagonist of the  $\alpha 4\beta 7$  integrin receptor and an antagonist of the  $\alpha 4\beta 1$  and  $\alpha 4\beta 7$  integrin receptors.

Claim <sup>41</sup>~~50~~. (Original) The method of claim <sup>38</sup>~~46~~ wherein the integrin mediated disorder is selected from the group consisting of inflammatory disorders, autoimmune disorders and cell-proliferative disorders.

Claim <sup>42</sup>~~51~~. (Original) The method of claim <sup>38</sup>~~46~~ wherein the integrin mediated disorder is selected from the group consisting of inflammation disorders, autoimmunity disorders, asthma, bronchoconstriction, restenosis, atherosclerosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, irritable bowel disease, irritable bowel syndrome, transplant rejection and multiple sclerosis.

Claim <sup>43</sup>~~52~~. (Previously Amended) The method of claim <sup>38</sup>~~46~~ wherein the integrin mediated disorder is selected from the group consisting of asthma, bronchoconstriction, restenosis, atherosclerosis, psoriasis, rheumatoid arthritis, inflammatory bowel disease, irritable bowel disease, irritable bowel syndrome, transplant rejection and multiple sclerosis.

Claim <sup>44</sup>~~53~~. (Previously Amended) The method of claim <sup>38</sup>~~46~~ wherein the integrin mediated disorder is selected from the group consisting of asthma, bronchoconstriction, restenosis, atherosclerosis, irritable bowel syndrome and multiple sclerosis.

Serial No. 09/891,602

<sup>45</sup> Claim ~~54~~. (Original) The method of claim <sup>38</sup>~~46~~ wherein the therapeutically effective amount of the compound of claim 1 is from about 0.01 mg/kg/day to about 300 mg/kg/day.

<sup>46</sup> Claim ~~55~~. (Previously Amended) The method of claim <sup>38</sup>~~46~~ further comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition of compound of claim 1 and a pharmaceutically acceptable excipient.

<sup>47</sup> Claim ~~56~~. (Previously Amended) The method of claim <sup>46</sup>~~55~~ wherein the therapeutically effective amount of the pharmaceutical composition of compound of claim 1 and a pharmaceutically acceptable excipient is from about 0.01 mg/kg/day to about 300 mg/kg/day.

<sup>48</sup> Claim ~~57~~. (Original) The compound of claim 1 wherein R<sub>1</sub> is selected from the group consisting tolyl, phenyl and thienyl.

<sup>49</sup> Claim ~~58~~. (Previously Amended) The method of claim <sup>38</sup>~~46~~ wherein the integrin mediated disorder is a cell-proliferation disorders.